theMednetRegister

Endocrinology

Hematology   

Questions discussed in this category

Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
2 Answers available
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
4 Answers available
When would you treat mild anemia from low testosterone in an older male?
Would you consider testosterone therapy if he is otherwise asymptomatic?
2 Answers available
How would you counsel a female to male transgender patient regarding VTE risk with testosterone therapy, who has additional mild-moderate risk factors for thrombosis?
Additional risk factors could be family history of VTE or thrombophilia, such as antithrombin deficiency.
1 Answer available
How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?
1 Answer available
Would you give transdermal hormone replacement therapy to a woman with remote history of provoked pulmonary embolism?
Is patch or gel HRT with ASA prophylaxis a reasonable option after counseling? Or do you add a prophylactic DOAC? 
1 Answer available
In a young female with severe osteoporosis due to congenital estrogen deficiency, can estrogen be prescribed if genetic testing for congenital disorders reveals a heterozygous Factor V Leiden mutation?
No prior thrombosis; no family history of thrombosis. As per endocrine, the only useful therapy for the osteoporosis is estrogen. 
1 Answer available
Do you treat secondary erythrocytosis caused by SGLT2 inhibitor?
1 Answer available
What recommendations do you have for a transgender female patient with history of prothrombin gene mutation who is interested in starting gender affirming hormone therapy?
The patient has no personal history of VTE, but has positive family history of VTE.  Any prophylactic anticoagulation options? How would manage...
1 Answer available
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
How do you counsel male-to-female transgender patients on the VTE risk of hormonal therapy?
1 Answer available
Do you routinely offer a bisphosphonate or denosumab to multiple myeloma patients without skeletal lesions?
Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).
2 Answers available


Papers discussed in this category

BMJ, 2008 May 20
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
Circulation,
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Cancer,
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Blood, 2013-10-24
The impact of response on bone-directed therapy in patients with multiple myeloma.
The Lancet. Oncology, 2011-08
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
The Lancet. Oncology, 2018-03
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Post reproductive health, 2022 Dec 27
Hormone replacement therapy in women with history of thrombosis or a thrombophilia.
Journal of thrombosis and haemostasis : JTH, 2019 Sep 13
Transgender patients and the role of the coagulation clinician.
The Journal of clinical endocrinology and metabolism, 2024 Jan 18
Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories.
Journal of the Endocrine Society, 2022 Dec 02
Perioperative Evaluation and Management of Patients on Glucocorticoids.
Diagnostics (Basel, Switzerland), 2021 Apr 20
Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.
The Journal of clinical endocrinology and metabolism, 2018 May 01
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The Journal of urology, 2022 Jan 20
Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy.
Haematologica, 2009 Oct 14
Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.
American journal of hematology, 2023 Jul 20
Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases.

Related Topics in Endocrinology

Copyright © 2024 theMednet
All Rights Reserved.